NCT06618287 · Bristol-Myers Squibb
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
What this study is about
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary effectiveness of BMS-986507 combinations in adult participants with advanced solid tumors.
View original scientific description
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Interventions
DRUG
BMS-986507
Specified dose on specified days
DRUG
Osimertinib
Specified dose on specified days
DRUG
Pembrolizumab
Specified dose on specified days
DRUG
Nivolumab
Specified dose on specified days
DRUG
Pumitamig
Specified dose on specified days
Primary outcome measures
Number of participants with adverse events (AEs)
Time frame: Up to 3 years
Number of participants with serious adverse events (SAEs)
Time frame: Up to 3 years
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera
Time frame: Up to 3 years
Number of participants with AEs leading to discontinuation
Time frame: Up to 3 years
Number of participants with AEs leading to death
Time frame: Up to 3 years
Number of DLTs that occur during the DLT evaluation period
Time frame: Up to 3 weeks
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Participants must have a life expectancy of at least 3 months at the time of the first dose.
- Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed
- Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.
- Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.
Where
- Birmingham, Alabama
- Miami, Florida
- Maywood, Illinois
- Iowa City, Iowa
- Hackensack, New Jersey
- Cleveland, Ohio
- Columbus, Ohio
- Portland, Oregon
- Pittsburgh, Pennsylvania
- Knoxville, Tennessee
- Irving, Texas
- Seattle, Washington
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 1, 2026 · Source of record for eligibility and locations